Hylly
Henkilönnimi Musso, Alberto, kirjoittaja.
Nimeke- ja vastuullisuusmerkintö Basic and Improvement Patents in COVID-19 Vaccines
Julkaistu Verlag C.H. Beck, München : 2022.
Ulkoasutiedot
Sarjamerkintö ei-lisäkirjausmuodossa GRUR International, ISSN 2632-8623 ; 71(5)
Huomautus sisällöstä, tiivistelmä tms. While measures to disseminate COVID vaccine patented technologies (compulsory licences, waivers, etc.) are often discussed [cf. Andreas Oser, ‘The COVID-19 Pandemic: Stress Test for Intellectual Property and Pharmaceutical Laws’, GRUR International 2021, 846 ff.], a less examined issue is the relationship between basic and improvement patents in this field. Enhanced technologies are frequently released due to the increasing incremental innovation model. Examples of such improvements are not only enhancements, but also – in a broader sense – new uses or side-shift functions of a basic invention in another field or a combination of two or more prior inventions. As a consequence, two main questions arise: (1) whether the improved technology is patentable in spite of the basic (or another prior overlapping) patent; and (2) if so, when the patentees are different, whether the second patent can be exploited without infringing the basic (or another prior overlapping) patent still in force.
Asiasana
Sarjalisäkirjaus - yhtenäistetty nimeke GRUR International, 2632-8623 ; 71(5)
*000 ab a ar
*00117150
*008 s2022||||gw |||||||||||||||||eng||
*040 $aFI-CUTE$bfin$erda
*0410 $aeng
*1001 $aMusso, Alberto,$ekirjoittaja.
*24510$aBasic and Improvement Patents in COVID-19 Vaccines /$cAlberto Musso.
*264 1$aMünchen :$bVerlag C.H. Beck,$c2022.
*300 $as. 393–394
*336 $ateksti$btxt$2rdacontent
*337 $akäytettävissä ilman laitetta$bn$2rdamedia
*338 $anide$bnc$2rdacarrier
*4901 $aGRUR International,$x2632-8623 ;$v71(5)
*520 $aWhile measures to disseminate COVID vaccine patented technologies (compulsory licences, waivers, etc.) are often discussed [cf. Andreas Oser, ‘The COVID-19 Pandemic: Stress Test for Intellectual Property and Pharmaceutical Laws’, GRUR International 2021, 846 ff.], a less examined issue is the relationship between basic and improvement patents in this field. Enhanced technologies are frequently released due to the increasing incremental innovation model. Examples of such improvements are not only enhancements, but also – in a broader sense – new uses or side-shift functions of a basic invention in another field or a combination of two or more prior inventions. As a consequence, two main questions arise: (1) whether the improved technology is patentable in spite of the basic (or another prior overlapping) patent; and (2) if so, when the patentees are different, whether the second patent can be exploited without infringing the basic (or another prior overlapping) patent still in force.
*650 7$apandemiat$2yso/fin$0http://www.yso.fi/onto/yso/p10121
*650 7$aCOVID-19 $2yso/fin$0http://www.yso.fi/onto/yso/p38829
*650 7$apatentit$0http://www.yso.fi/onto/yso/p3069$2yso/fin
*650 7$ateollisoikeus$2yso/fin$0http://www.yso.fi/onto/yso/p3067
*650 7$arokotteet$0http://www.yso.fi/onto/yso/p15634$2yso/fin
*830 0$aGRUR International,$x2632-8623 ;$v71(5)
*852 $hSA-GRUR International
^
Tästä teoksesta ei ole arvioita.
Näpäytä
kun haluat kirjoittaa ensimmäisen arvion.